OakChart

Attovia Therapeutics Inc

ATTOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:04 AM ET

16.95+0.32 (1.89%)
2026-11-11 16:05 CET
Market cap
759.64 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-22.27 USD m
Free cash flow, TTM
-25.69 USD m
EPS diluted, TTM
-0.49
P/E
-
Compare

Price

ATTO against its 20 and 50-day averages
2050earnings
15.0020.0025.002.5M4.9MAug 26Sep 26Oct 26Nov 26ATTOclose 16.9620-day 14.9950-day 17.8616.96

39.4% under 28.00 on 8 Sep 2026. Last 15 sessions, 25.6% high to low

Profile

ATTO
52-week range, 27% of the way up
12.9428.00

Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA.

IPOAug 05, 2026
ATR, 14d1.46
Rel volume0.15
Short float5.58%
Insider own37.71%
Inst own16.20%

Snapshot

6 groups

Valuation

Index-
Market Cap775.06M
Enterprise Value382.96M
Income-
Sales-
Book/sh8.71
Cash/sh8.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOAug 05, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.95
P/C1.96
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio34.66
Current Ratio34.66
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.52
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-44.32%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.-36.72% -

Ownership

Insider Own37.71%
Insider Trans19.66%
Inst Own16.20%
Inst Trans12.85%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2013.10%
SMA50-5.08%
SMA200-9.09%
Trades-

Technical

Shs Outstand45.68M
Shs Float28.44M
Short Float5.58%
Short Ratio4.56
Short Interest1.59M
52W High28.00 -39.45%
52W Low12.94 31.03%
Volatility10.96% 9.85%
ATR (14)1.46
RSI (14)57.44
Beta-
Rel Volume0.15
Avg Volume348.31K
Volume6,998

Performance

Perf Week8.69%
Perf Month15.18%
Perf Quarter-11.60%
Perf Half Y-
Perf YTD-19.26%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price43.20
Prev Close16.64
Price16.95
Change %1.89%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Aug 31, 2026InitiatedRRBC Capital MktsOutperform$45+165.4%
Aug 31, 2026InitiatedMMorgan StanleyOverweight$39+130.0%
Aug 31, 2026InitiatedLLeerink PartnersOutperform$52+206.7%
Aug 31, 2026InitiatedCCitigroupBuy$30+76.9%

Peers

Mkt cap
TickerCompanyMkt cap
ALMSAlumis Inc870.39M
ANABAnaptysBio Inc1.46B
IMVTImmunovant Inc7.51B
ACRSAclaris Therapeutics Inc666.17M
UPBUpstream Bio Inc186.50M
SYRESpyre Therapeutics Inc9.94B
ETRAElectra Therapeutics Inc545.73M
KYMRKymera Therapeutics Inc11.69B
ABVXAbivax ADR8.00B
PTGXProtagonist Therapeutics Inc8.82B

Insider trading

12 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 05 '26Proposed Sale21.00105,8072,221,947Aug 28 05:50 PM
WALSH COLINDirectorAug 06 '26Buy17.00500,0008,500,0003,020,632Aug 13 09:52 PM
WALSH COLINDirectorAug 05 '26Buy21.0085,0001,785,00085,000Aug 13 09:52 PM
WALSH COLINDirectorAug 05 '26Sale21.28105,8072,251,6580Aug 13 09:52 PM
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 06 '26Buy17.00500,0008,500,0003,020,632Aug 13 09:51 PM
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 05 '26Buy21.0085,0001,785,00085,000Aug 13 09:51 PM
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 05 '26Sale21.28105,8072,251,6580Aug 13 09:51 PM
venBio Global Strategic Fund I10% OwnerAug 06 '26Buy17.00382,3526,499,9844,181,367Aug 10 04:12 PM
Redmile Group, LLC10% OwnerAug 06 '26Buy17.00400,0006,800,0001,182,854Aug 07 09:47 PM
Redmile Group, LLC10% OwnerAug 06 '26Buy17.00200,0003,400,000982,854Aug 07 09:47 PM
Sanofi10% OwnerAug 06 '26Buy17.00300,0005,100,0001,082,855Aug 07 03:45 PM
Frazier Life Sciences XI, L.P.10% OwnerAug 06 '26Buy17.00588,2359,999,9956,154,213Aug 06 05:35 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.760-0.556-0.000.004
2026Q22026-09-02-4.882-0.646-0.4530.450.322
2026Q12026-06-03-0.607--0.4090.00--
2026Q4---0.517--0.004
2027Q1---0.591--0.001
2027Q2---0.591--0.001
2027Q3---0.591--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-102000.000.000.00
2026Q4S2026-11-092000.000.000.00
2026Q4S2026-09-032000.000.000.00
2026Q4S2026-08-312000.000.000.00
2026Q4S2026-08-281000.000.000.00
2026Q4E2026-11-10413-0.52-0.58-0.47
2026Q4E2026-11-09411-0.49-0.57-0.36
2026Q4E2026-09-03411-0.49-0.57-0.36
2026Q4E2026-09-01401-0.50-0.57-0.37
2026Q4E2026-08-31400-0.49-0.57-0.37
2026Q4E2026-08-28300-0.54-0.57-0.51
2026Q3S2026-09-032000.000.000.00
2026Q3S2026-09-022000.000.000.00
2026Q3S2026-08-312000.000.000.00

Estimate history

EPS, annual-0.987-1.334
Period20242025
EPS, quarterly-0.338-0.316-0.409-0.453-0.488
PeriodQ1 '25Q2 '25Q1 '26Q2 '26Q3 '26
Sales, annual01.35
Period20242025
Sales, quarterly0000.450
PeriodQ1 '25Q2 '25Q1 '26Q2 '26Q3 '26
Shares, annual45.65145.65145.683
Period20242025MRQ
Shares, quarterly45.65145.65145.65145.65145.683
PeriodQ1 '25Q2 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.001.350.00
Cost of Goods Sold Incl. D&A0.250.800.31
Gross Profit-0.250.55-0.31
Selling, General and Administrative Excl. Other24.7867.7041.24
Research and Development20.2954.1533.86
Other Operating Expense0.000.000.00
Operating Income-25.02-67.16-41.55
Interest Expense0.000.000.00
Unusual Expense0.000.171.67
Net Income Before Taxes-22.27-60.63-39.80
Income Taxes0.000.000.00
Consolidated Net Income-22.27-60.90-45.05
Net Income From Continuing Operations-22.27-60.90-45.05
Net Income-22.27-60.90-45.05
EPS (Recurring)-0.49-1.33-0.96
EPS (Basic, Before Extraordinaries)-0.49-1.33-0.99
EPS (Diluted)-0.49-1.33-0.99
EBITDA-24.78-66.36-41.24
Non-Operating Income (Expense)2.756.703.43
Other After Tax Adjustments0.00-0.27-5.25
Stock Option Compensation Expense1.632.391.39
Gross Margin-40.44-
Operating Margin--4,974.74-
Net Margin--4,510.96-
Shares Outstanding45.6845.6545.65
Market Capitalization759.64759.64-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q22025Q1
Total Revenue0.000.450.000.000.00
Cost of Goods Sold Incl. D&A0.250.250.240.210.14
Gross Profit-0.250.20-0.24-0.21-0.14
Selling, General and Administrative Excl. Other24.7822.0119.7116.4115.96
Research and Development20.2918.9516.7513.5911.86
Other Operating Expense0.000.000.000.000.00
Operating Income-25.02-21.80-19.95-16.62-16.10
Interest Expense0.000.000.000.000.00
Unusual Expense0.000.000.000.000.17
Net Income Before Taxes-22.27-20.69-18.66-14.44-15.15
Income Taxes0.000.000.000.000.00
Consolidated Net Income-22.27-20.69-18.66-14.44-15.42
Net Income From Continuing Operations-22.27-20.69-18.66-14.44-15.42
Net Income-22.27-20.69-18.66-14.44-15.42
EPS (Recurring)-0.49-0.45-0.41-0.32-0.34
EPS (Basic, Before Extraordinaries)-0.49-0.45-0.41-0.32-0.34
EPS (Diluted)-0.49-0.45-0.41-0.32-0.34
EBITDA-24.78-21.56-19.71-16.41-15.96
Non-Operating Income (Expense)2.751.121.302.181.12
Other After Tax Adjustments0.000.000.000.00-0.27
Stock Option Compensation Expense1.630.690.690.560.46
Gross Margin-45.33---
Operating Margin--4,845.11---
Net Margin--4,597.11---
Shares Outstanding45.6845.6545.6545.6545.65
Market Capitalization759.64829.03---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments152.2769.32
Short Term Receivables0.000.00
Inventories0.000.00
Other Current Assets4.033.16
Total Current Assets156.2972.48
Net Property, Plant & Equipment7.873.23
Total Investments and Advances0.400.61
Other Assets1.330.39
Total Assets165.8976.72
Short Term Debt Incl. Current Port. of LT Debt1.920.00
Accounts Payable3.554.14
Other Current Liabilities5.543.58
Total Current Liabilities11.017.72
Long Term Debt3.340.00
Provision for Risks Charges0.000.00
Other Liabilities0.766.87
Total Liabilities15.1014.59
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value258.23108.95
Common Equity-107.44-46.83
Total Shareholders Equity150.7962.13
Accumulated Minority Interest0.000.00
Total Equity150.7962.13
Total Liabilities & Stockholders Equity165.8976.72
Book Value Per Share-2.35-1.03
Tangible Book Value Per Share-2.35-1.03
Price to Book Ratio1.91-
Return on Assets-50.20-
Return on Equity-57.20-
Return on Invested Capital-39.51-72.51
Quick Ratio14.209.39
Current Ratio14.209.39

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-22.27-60.63-39.80
Depreciation0.250.800.31
Other Funds (Non Cash)1.850.352.92
Funds from Operations-20.18-59.48-36.57
Extraordinary Item0.000.000.00
Changes in Working Capital-5.500.281.54
Cash from Operating Activities-25.67-59.20-35.03
Capital Expenditures-0.02-2.31-1.77
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments-199.73-71.14-38.03
Purchase of Investments-228.63-221.89-46.03
Sale Or Maturity of Investments28.90150.758.00
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities-199.75-73.45-39.80
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock307.50142.0182.92
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock307.50142.0182.92
Proceedsfrom Stock Options307.21141.8282.61
Issuance or Reduction of Debt, Net0.000.00-0.17
Change in Long Term Debt0.000.00-0.17
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.00-0.17
Net Financing Active Other Cash Flow0.450.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities307.96142.0182.75
Net Change in Cash82.549.367.91
Free Cash Flow-25.69-61.51-36.81
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q22025Q1
Cash & Short Term Investments395.94115.13132.62--
Short Term Receivables2.500.000.00--
Inventories0.000.000.00--
Other Current Assets6.083.274.02--
Total Current Assets404.52118.40136.64--
Net Property, Plant & Equipment6.326.927.49--
Total Investments and Advances0.400.400.40--
Other Assets0.592.621.55--
Total Assets411.82128.35146.09--
Short Term Debt Incl. Current Port. of LT Debt2.102.041.98--
Accounts Payable4.226.002.56--
Other Current Liabilities5.354.585.26--
Total Current Liabilities11.6712.629.80--
Long Term Debt1.742.292.83--
Provision for Risks Charges0.000.000.00--
Other Liabilities0.670.680.75--
Total Liabilities14.0815.5813.38--
Non-Equity Reserves0.000.000.00--
Preferred Stock - Carrying Value0.00258.23258.23--
Common Equity397.74-145.46-125.52--
Total Shareholders Equity397.74112.77132.71--
Accumulated Minority Interest0.000.000.00--
Total Equity397.74112.77132.71--
Total Liabilities & Stockholders Equity411.82128.35146.09--
Book Value Per Share8.71-3.19-2.75--
Tangible Book Value Per Share8.71-3.19-2.75--
Full-Time Employees-4444--
Price to Book Ratio1.91-5.70---
Return on Invested Capital-5.57-17.98-13.76--
Quick Ratio34.669.3913.94--
Current Ratio34.669.3913.94--

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q22025Q1
Net Income-22.27-20.69-18.66-14.44-15.15
Depreciation0.250.250.240.210.14
Other Funds (Non Cash)1.851.010.810.140.85
Funds from Operations-20.18-19.43-17.60-14.09-14.16
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-5.502.64-0.541.530.03
Cash from Operating Activities-25.67-16.79-18.14-12.57-14.13
Capital Expenditures-0.02-0.07-0.29-0.09-1.79
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-199.736.9522.77-74.07-27.50
Purchase of Investments-228.63-27.95-20.23-93.32-45.50
Sale Or Maturity of Investments28.9034.9043.0019.2518.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-199.756.8822.49-74.17-29.29
Cash Dividends Paid0.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.00
Change in Capital Stock307.50-0.56-1.240.07141.89
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock307.50-0.56-1.240.07141.89
Proceedsfrom Stock Options307.21-0.59-1.25-0.03141.85
Issuance or Reduction of Debt, Net0.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.450.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities307.96-0.56-1.240.07141.89
Net Change in Cash82.54-10.473.10-86.6698.47
Free Cash Flow-25.69-16.86-18.43-12.66-15.92

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.58%1.6M28.4M432.76K
2026-10-155.11%1.5M28.4M448.90K
2026-09-305.81%1.6M28.4M456.24K
2026-09-152.93%0.8M28.4M413.00K
2026-08-312.28%0.6M28.4M520.04K
2026-08-141.87%0.5M27.3M939.90K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-084/A2026-08-04SEC
2026-10-083/A2026-08-04SEC
2026-10-084/A2026-08-04SEC
2026-10-083/A2026-08-04SEC
2026-09-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-028-KCurrent report2026-09-02SEC
2026-08-284/A2026-08-05SEC
2026-08-28144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284/A2026-08-05SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-12SCHEDULE 13GSEC
2026-08-11SCHEDULE 13DSEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0852.37M94.50M2
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Sanofi2.37%
FMR LLC0.71%
GEODE CAPITAL MANAGEMENT, LLC0.45%
UBS Group AG0.40%
Squarepoint Ops LLC0.09%
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.0.03%
CITIGROUP INC0.00%

Funds

Fund% owned
Select Biotechnology Portfolio1.54%
Fidelity Nasdaq Composite Index Fund0.09%
Strategic Advisers U.S. Total Stock Fund0.08%
VANGUARD RUSSELL 2000 INDEX FUND0.04%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.00%
VANGUARD RUSSELL 2000 VALUE INDEX FUND0.00%
VANGUARD RUSSELL 3000 INDEX FUND0.00%

OakChart. ATTO. Cached 15 minutes.

Some panels did not load: news.